StageZero Life Sciences (OTCMKTS:GNWSF) and StageZero Life Sciences (OTCMKTS:SZLSF) Head-To-Head Survey

StageZero Life Sciences (OTCMKTS:GNWSFGet Rating) and StageZero Life Sciences (OTCMKTS:SZLSFGet Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Profitability

This table compares StageZero Life Sciences and StageZero Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
StageZero Life Sciences -200.26% N/A -165.13%
StageZero Life Sciences -147.77% N/A -169.49%

Insider and Institutional Ownership

0.0% of StageZero Life Sciences shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

StageZero Life Sciences has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, StageZero Life Sciences has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Valuation & Earnings

This table compares StageZero Life Sciences and StageZero Life Sciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
StageZero Life Sciences $4.15 million 5.46 -$6.86 million N/A N/A
StageZero Life Sciences $5.07 million 1.48 -$7.48 million ($0.10) -0.75

StageZero Life Sciences has higher earnings, but lower revenue than StageZero Life Sciences.

Analyst Ratings

This is a summary of recent ratings for StageZero Life Sciences and StageZero Life Sciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
StageZero Life Sciences 0 0 0 0 N/A
StageZero Life Sciences 0 0 0 0 N/A

StageZero Life Sciences Company Profile (Get Rating)

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.

StageZero Life Sciences Company Profile (Get Rating)

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.

Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.